Directorate Change

RNS Number : 4455Z

Revolymer PLC

18 September 2015

 

18^th September, 2015

Revolymer plc

Directorate Change

Revolymer plc ("Revolymer" or the "Company"), announces that its Chairman of the Board of Directors ("Chairman"), Mr John "Jack" Keenan, has today retired from this role. After an externally led search process, Dr Bryan Dobson, an existing independent non executive director of Revolymer since 2012, has accepted the role of Chairman, succeeding Mr Keenan with immediate effect. Mr Keenan will remain on the Board as an independent non executive director to provide continuity until a replacement is recruited.

Mr Keenan has been a non executive director of the business since January 2008, and Chairman since the flotation on the AIM Market in July 2012. He has played a significant role throughout this period, applying his considerable experience to guiding the commercial development of the business as well providing advice on corporate governance.

Dr Dobson has extensive expertise in the specialty chemicals industry which is highly relevant to Revolymer's business plan. Specifically, he has nearly 40 years' experience in the chemicals industry, including with ICI plc and Croda International plc. He was a member of the executive management teams in Croda and in a number of large specialty chemicals businesses in ICI, and has extensive management experience running regional and global business units in the UK, US, Belgium and The Netherlands. He also has expertise in developing new business in specialty chemicals sectors; extensive functional experience in R&D and operations and significant M&A experience. Dr Dobson is currently Chairman of Applied Graphene Materials plc, an AIM listed specialty materials business, and a non-executive director of the Newcastle upon Tyne Hospitals NHS Foundation Trust, a major UK teaching hospital.

Kevin Matthews, Revolymer CEO, said "We would like to thank Jack for his valuable advice and guidance to Revolymer over a number of years as Chairman. Looking forward, we are delighted that Bryan has agreed to take up the role of Chairman given his strong track record in the specialty chemicals industry, and look forward to working with him to continue Revolymer's commercial development."

Ends

For further information please contact:

Revolymer plc	[phone]
Kevin Matthews / Rob Cridland
Panmure Gordon (UK) Limited	[phone]
Hugh Morgan / Adam James (Corporate Finance) Charles Leigh-Pemberton (Corporate Broking)

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) whose vision is to be a specialty chemicals business, leading in the development of controlled release, responsive systems and delivery systems that improve the functional performance of its customers' products. It aims to use its expertise in the design and synthesis of polymers, often in combination with other materials, to manage the interface between different surfaces and phases to solve customers' problems, thereby generating high margin business.

www.revolymer.com

About Revolymer

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG and other industrial markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within these global high value markets. Current applications for the Group's technologies are in the household products, personal care and coatings & adhesives markets (together "Consumer Specialties") and the medicated chewing gum and confectionery chewing gum (together "Gum") markets.

www.revolymer.com

 

END

 

 

BOAUBVNRVOAKAAR